Eric Joseph
Stock Analyst at JP Morgan
(2.02)
# 3,074
Out of 5,134 analysts
124
Total ratings
38.1%
Success rate
-5.31%
Average return
Main Sectors:
Stocks Rated by Eric Joseph
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RXRX Recursion Pharmaceuticals | Upgrades: Overweight | $10 → $11 | $3.46 | +217.92% | 3 | Dec 17, 2025 | |
| TGTX TG Therapeutics | Maintains: Overweight | $46 → $49 | $29.06 | +68.62% | 5 | Nov 3, 2025 | |
| BEAM Beam Therapeutics | Maintains: Overweight | $48 → $46 | $27.49 | +67.33% | 4 | Oct 9, 2025 | |
| KYMR Kymera Therapeutics | Maintains: Overweight | $57 → $64 | $84.84 | -24.56% | 4 | Jun 3, 2025 | |
| RCKT Rocket Pharmaceuticals | Downgrades: Neutral | $44 → $7 | $3.31 | +111.48% | 4 | May 28, 2025 | |
| PRME Prime Medicine | Downgrades: Neutral | n/a | $3.31 | - | 5 | May 20, 2025 | |
| NVAX Novavax | Maintains: Underweight | $9 → $7 | $8.65 | -19.08% | 8 | May 9, 2025 | |
| PTCT PTC Therapeutics | Maintains: Overweight | $75 → $67 | $69.17 | -3.14% | 10 | May 7, 2025 | |
| OPK OPKO Health | Initiates: Neutral | n/a | $1.22 | - | 4 | Apr 25, 2025 | |
| PLRX Pliant Therapeutics | Downgrades: Neutral | n/a | $1.13 | - | 4 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $31 → $30 | $15.64 | +91.82% | 7 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $10 → $14 | $7.50 | +86.67% | 5 | Jan 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $63 → $71 | $100.61 | -29.43% | 6 | Dec 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $38 | $30.30 | +25.41% | 1 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $23 | $4.06 | +466.50% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $13 → $17 | $12.59 | +35.03% | 2 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $21 | $9.16 | +129.26% | 5 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $11 → $10 | $13.89 | -28.01% | 4 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $15 | $1.33 | +1,027.82% | 1 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $6 | $1.83 | +227.87% | 4 | Jan 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $31 → $11 | $18.36 | -40.09% | 2 | Oct 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $300 → $100 | $25.38 | +294.01% | 1 | Aug 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $28 → $5 | $1.93 | +159.07% | 2 | Aug 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $4.60 | - | 6 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $10 → $11 | $39.58 | -72.21% | 6 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $24.75 | - | 2 | Nov 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $120 | $9.40 | +1,176.60% | 2 | Feb 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $750 → $300 | $6.68 | +4,391.02% | 2 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $11.93 | - | 2 | Oct 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $24 → $9 | $1.51 | +496.03% | 2 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $1.20 | - | 4 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $42 | $2.23 | +1,783.41% | 1 | Feb 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $11 → $13 | $4.78 | +171.97% | 2 | Jan 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $35 → $11 | $0.37 | +2,872.97% | 3 | Nov 14, 2018 |
Recursion Pharmaceuticals
Dec 17, 2025
Upgrades: Overweight
Price Target: $10 → $11
Current: $3.46
Upside: +217.92%
TG Therapeutics
Nov 3, 2025
Maintains: Overweight
Price Target: $46 → $49
Current: $29.06
Upside: +68.62%
Beam Therapeutics
Oct 9, 2025
Maintains: Overweight
Price Target: $48 → $46
Current: $27.49
Upside: +67.33%
Kymera Therapeutics
Jun 3, 2025
Maintains: Overweight
Price Target: $57 → $64
Current: $84.84
Upside: -24.56%
Rocket Pharmaceuticals
May 28, 2025
Downgrades: Neutral
Price Target: $44 → $7
Current: $3.31
Upside: +111.48%
Prime Medicine
May 20, 2025
Downgrades: Neutral
Price Target: n/a
Current: $3.31
Upside: -
Novavax
May 9, 2025
Maintains: Underweight
Price Target: $9 → $7
Current: $8.65
Upside: -19.08%
PTC Therapeutics
May 7, 2025
Maintains: Overweight
Price Target: $75 → $67
Current: $69.17
Upside: -3.14%
OPKO Health
Apr 25, 2025
Initiates: Neutral
Price Target: n/a
Current: $1.22
Upside: -
Pliant Therapeutics
Feb 10, 2025
Downgrades: Neutral
Price Target: n/a
Current: $1.13
Upside: -
Jan 29, 2025
Maintains: Overweight
Price Target: $31 → $30
Current: $15.64
Upside: +91.82%
Jan 9, 2025
Maintains: Neutral
Price Target: $10 → $14
Current: $7.50
Upside: +86.67%
Dec 3, 2024
Maintains: Overweight
Price Target: $63 → $71
Current: $100.61
Upside: -29.43%
Nov 19, 2024
Initiates: Overweight
Price Target: $38
Current: $30.30
Upside: +25.41%
Nov 5, 2024
Initiates: Overweight
Price Target: $23
Current: $4.06
Upside: +466.50%
Oct 17, 2024
Maintains: Overweight
Price Target: $13 → $17
Current: $12.59
Upside: +35.03%
Sep 10, 2024
Maintains: Overweight
Price Target: $23 → $21
Current: $9.16
Upside: +129.26%
Aug 6, 2024
Maintains: Underweight
Price Target: $11 → $10
Current: $13.89
Upside: -28.01%
May 3, 2024
Maintains: Neutral
Price Target: $14 → $15
Current: $1.33
Upside: +1,027.82%
Jan 29, 2024
Upgrades: Neutral
Price Target: $6
Current: $1.83
Upside: +227.87%
Oct 19, 2023
Maintains: Overweight
Price Target: $31 → $11
Current: $18.36
Upside: -40.09%
Aug 28, 2023
Downgrades: Neutral
Price Target: $300 → $100
Current: $25.38
Upside: +294.01%
Aug 28, 2023
Downgrades: Neutral
Price Target: $28 → $5
Current: $1.93
Upside: +159.07%
Aug 10, 2023
Downgrades: Underweight
Price Target: n/a
Current: $4.60
Upside: -
Aug 9, 2023
Maintains: Neutral
Price Target: $10 → $11
Current: $39.58
Upside: -72.21%
Nov 29, 2022
Downgrades: Underweight
Price Target: n/a
Current: $24.75
Upside: -
Feb 9, 2022
Upgrades: Neutral
Price Target: $120
Current: $9.40
Upside: +1,176.60%
Jan 7, 2022
Downgrades: Neutral
Price Target: $750 → $300
Current: $6.68
Upside: +4,391.02%
Oct 8, 2021
Downgrades: Underweight
Price Target: n/a
Current: $11.93
Upside: -
Jan 29, 2021
Downgrades: Neutral
Price Target: $24 → $9
Current: $1.51
Upside: +496.03%
Jan 29, 2021
Downgrades: Underweight
Price Target: n/a
Current: $1.20
Upside: -
Feb 24, 2020
Initiates: Overweight
Price Target: $42
Current: $2.23
Upside: +1,783.41%
Jan 24, 2019
Upgrades: Neutral
Price Target: $11 → $13
Current: $4.78
Upside: +171.97%
Nov 14, 2018
Maintains: Neutral
Price Target: $35 → $11
Current: $0.37
Upside: +2,872.97%